WSW, NY, April 23rd, 2026, FinanceWire
A 60-Year-Old Drug vs. a 5-Day Solution: Why Wound Care Giants Are Watching MediWound
The advanced wound care market is in the middle of a significant shakeup. Medicare is dismantling large portions of the cellular and tissue-based product (CTP) reimbursement landscape, and companies dependent on that segment are facing real uncertainty. But one company developing a true biologic drug for wound care continues to move steadily through its clinical program. That company is MediWound (Nasdaq: MDWD), and its lead pipeline asset is EscharEx, a bromelain-based biologic therapy designed for enzymatic debridement, the process of removing dead or damaged tissue from chronic wounds so they can begin to heal. At a time when the wound care industry is searching for durable, clinically validated solutions, EscharEx has begun to attract increasing attention from both investors and industry players.
Why does a new debridement drug matter? Because the standard pharmaceutical option available today has barely changed in over half a century. Collagenase SANTYL ointment, the only widely used enzymatic debridement product in the United States, was introduced in 1965 and still generates an estimated $400 million in annual U.S. sales. Yet SANTYL often requires weeks or months of treatment to remove necrotic tissue from a wound. Clinical studies suggest that EscharEx may accomplish debridement in as few as five days. In a head-to-head subgroup analysis from MediWound’s Phase II ChronEx trial, 63% of patients treated with EscharEx achieved complete debridement within two weeks, compared to 0% of patients treated with SANTYL. The median time to complete debridement was nine days for EscharEx; for SANTYL, that endpoint was not achieved. If those results hold through Phase III and regulatory review, EscharEx could represent one of the most meaningful advances in wound bed preparation in decades.
Importantly, MediWound is not pursuing this opportunity alone. A growing roster of global wound care leaders has entered into research collaboration agreements with the company to support the EscharEx clinical program. Coloplast/Kerecis, ConvaTec, Essity, Molnlycke Health Care, Solventum, and MIMEDX are all providing their wound care products for use as standard-of-care treatments in both arms of MediWound’s clinical trials. In return, these companies receive clinical data showing how their products perform as standard of care in a large drug study, information that could serve as a powerful marketing asset. Just as importantly, these collaborations allow the companies to establish closer working relationships with MediWound as EscharEx advances toward commercialization.
The most recent addition to that list may be the most notable. In its fourth quarter 2025 earnings release, MediWound announced that B. Braun, the German medical technology company with more than $9 billion in annual revenue, had joined the EscharEx clinical program through a research collaboration agreement. B. Braun will participate in the planned Phase II study evaluating EscharEx in diabetic foot ulcers, one of two new indications MediWound is pursuing in addition to its ongoing Phase III VALUE trial in venous leg ulcers. A separate investigator-initiated trial in pressure ulcers is also planned for the second half of 2026. Together, these three indications represent the major categories of chronic wounds, a market that MediWound estimates at more than $2.5 billion in the U.S. alone.
This momentum extends beyond EscharEx. In early April, MediWound’s North American partner Vericel (NASDAQ: VCEL) was awarded a ten-year BARDA contract valued at up to $197 million for NexoBrid, adding a significant revenue stream alongside the company’s chronic wound pipeline. Between a growing list of industry collaborators, an expanding clinical program, and now another major government contract, MediWound appears to be assembling the kind of platform that could attract serious strategic interest as EscharEx advances toward commercialization.
Read this Next >> Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex (NASDAQ: CPIX)
Recent News Highlights from MediWound (MDWD)
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
MediWound to Present New EscharEx Data at Leading Wound Care Conferences
MediWound Reports BARDA Contract Award to Vericel for NexoBrid Valued at up to $197 Million
MediWound Files Annual Report on Form 20-F
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from MediWound Ltd for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the issuer.